Perrigo Company plc announced it has received final approval from the U.S. Food and Drug Administration for the generic version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%). Estrace® Cream is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Market sales of Estrace® Cream over the last 12 months were approximately $457 million, according to IMS Health.